← All trials
NCT06943404
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 29, 2025
- Primary completion
- Sep 29, 2026
- Completion date
- Sep 29, 2026
- First posted
- Apr 24, 2025
- Last posted
- Jul 28, 2025
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of North Carolina at Chapel HillLead sponsor
- University of FloridaCollaborator
- Vanderbilt UniversityCollaborator
- Department of DefenseCollaborator
- Rhode Island HospitalCollaborator
- Mclean HospitalCollaborator
- United States ArmyCollaborator
- Washington University in St. LouisCollaborator
- Washington University in St. LouisOfficial
- University of North Carolina at Chapel HillOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.